Monday, 21 December 2020

Covaxin Crosses Half-Way Mark In Phase-3 Trials, Says Bharat Biotech

India's first and only phase III trial of a COVID-19 vaccine has crossed 13,000 subjects - the half-way mark - and proceeding successfully across multiple sites in India, Bharat Biotech, the maker of...

from NDTV News - India-news https://ift.tt/3rtOTBw
at
Labels: , ,

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

Opposition Notice On Motion To Remove Poll Body Chief Rejected In Parliament

In separate orders, the Speaker and the Rajya Sabha Chairman refused to admit the notices moved under Article 324(5) of the Constitution. ...